Alpha 1D Adrenergic Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ADRA1D Protein - Alpha-1D Adrenergic Receptor Protein
| Protein Name | Alpha-1D Adrenergic Receptor Protein |
| Gene | ADRA1D |
| UniProt ID | P25100 |
| PDB ID | 6G9R |
| Molecular Weight | 60 kDa |
| Subcellular Localization | Cell membrane, CNS and periphery |
| Protein Family | Adrenergic receptor (Class A, GPCR) |
Alpha-1D has the typical 7-transmembrane domain structure. It has a distinctive long third intracellular loop (IL3) which is important for G protein coupling specificity. The receptor contains conserved motifs including the DRY motif. It forms both homodimers and heterodimers with other alpha-1 adrenergic subtypes.
The alpha-1D adrenergic receptor is a Gq protein-coupled receptor that activates phospholipase C, leading to increased IP3 and DAG production, and subsequent intracellular calcium release. It mediates the effects of norepinephrine and epinephrine on smooth muscle contraction. In the brain, it is involved in modulating attention, arousal, and stress responses.
Alpha-1D receptors are implicated in Parkinson's disease and Alzheimer's disease through effects on cerebral blood flow and autonomic function. Dysregulation may contribute to cardiovascular comorbidities in neurodegenerative diseases. The receptor is also involved in hypertension and benign prostatic hyperplasia.
Alpha-1D selective antagonists (e.g., silodosin) are used clinically for benign prostatic hyperplasia. In development are compounds for treating hypertension and urinary symptoms. Brain-penetrant antagonists may have potential for neurodegenerative diseases.
ADRA1D is expressed in:
- Brain: Cortex, hippocampus, basal ganglia, brainstem
- Peripheral tissues: Vascular smooth muscle, prostate, eye
ADRA1D antagonists have been explored for:
- Hypertension: Tamsulosin, Silodosin
- Benign prostatic hyperplasia: Improved urinary flow
- Potential neuroprotective effects: Under investigation
- ADRA1D polymorphisms and neuropsychiatric disorders
- Role in cerebral blood flow regulation
- Novel therapeutic applications
Research on Alpha-1D Adrenergic Receptor has revealed important implications for neurodegenerative diseases.
- Biomarker development
- Therapeutic targeting
- Disease mechanism studies
The study of Alpha 1D Adrenergic Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Garcia-Sainz et al. (1999). Alpha-1D adrenergic receptors. Pharmacol Rev. PMID:10417670.
- Piascik et al. (2001). Alpha-1D receptor function in the brain. CNS Drugs. PMID:11524036.
- Daly et al. (2002). ADRA1D variants and hypertension. Hypertension. PMID:12411324.
- Ziegler et al. (2011). Alpha-1D receptors in neurodegeneration. J Neural Transm. PMID:21335586.
- Chen et al. (2015). Alpha-1D antagonists for LUTS. Nat Rev Urol. PMID:25800316.
ADRA1D is expressed in:
- Brain: Cortex, hippocampus, basal ganglia, brainstem
- Peripheral tissues: Vascular smooth muscle, prostate, eye
ADRA1D antagonists have been explored for:
- Hypertension: Tamsulosin, Silodosin
- Benign prostatic hyperplasia: Improved urinary flow
- Potential neuroprotective effects: Under investigation
- ADRA1D polymorphisms and neuropsychiatric disorders
- Role in cerebral blood flow regulation
- Novel therapeutic applications
Research on Alpha-1D Adrenergic Receptor has revealed important implications for neurodegenerative diseases.
- Biomarker development
- Therapeutic targeting
- Disease mechanism studies
-
[1] J. P. B. Summers et al., "Adrenergic receptor signaling in neurodegeneration," Progress in Lipid Research, vol. 63, pp. 30-45, 2016. PMID:27067906
-
[2] A. C. N. Lefkowitz et al., "Beta-adrenergic receptors in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 45, no. 4, pp. 1023-1034, 2015. PMID:25649654
This section provides an overview of the structure and function.
The Alpha-1D adrenergic receptor activates multiple intracellular signaling cascades:
- Phospholipase C activation: Generates IP3 and DAG
- Calcium mobilization: Intracellular calcium release
- Protein kinase C activation: DAG-dependent PKC activation
- MAPK pathway activation: ERK1/2 phosphorylation
- RhoA/ROCK pathway: Cytoskeletal reorganization
- cAMP modulation: Through cross-talk mechanisms
- Calcium influx: Via voltage-gated calcium channels
¶ Expression and Distribution
- Spinal cord: Dorsal horn neurons
- Brainstem: Cardiovascular control centers
- Cortex: Moderate expression
- Hypothalamus: Neuroendocrine regulation
- Vascular smooth muscle: Vasoconstriction
- Heart: Cardiac contractility
- Liver: Metabolic regulation
- Prostate: Smooth muscle tone
- Vasoconstriction of resistance vessels
- Blood pressure maintenance
- Baroreceptor reflex modulation
- Cardiac preload regulation
- Pain modulation in spinal cord
- Stress response coordination
- Arousal and attention
- Neuroendocrine control
- Dysregulated alpha-1D signaling
- Potential orthostatic hypotension
- Autonomic dysfunction
- Vascular contributions to pathology
- Cerebral blood flow regulation
- Neuroinflammation modulation
¶ Depression and Anxiety
- Stress-induced signaling
- Treatment targets
- Receptor downregulation
- Prazosin: Selective alpha-1 antagonist
- Terazosin: FDA approved for BPH
- Doxazosin: Long-acting formulation
- Hypertension treatment
- Benign prostatic hyperplasia
- PTSD nightmares
- Raynaud's phenomenon
- Subtype-selective ligands
- Brain-penetrating antagonists
- PET imaging tracers
- Gene therapy approaches
ADRA1D is expressed in:
- Brain: Cortex, hippocampus, basal ganglia, brainstem
- Peripheral tissues: Vascular smooth muscle, prostate, eye
ADRA1D antagonists have been explored for:
- Hypertension: Tamsulosin, Silodosin
- Benign prostatic hyperplasia: Improved urinary flow
- Potential neuroprotective effects: Under investigation
- ADRA1D polymorphisms and neuropsychiatric disorders
- Role in cerebral blood flow regulation
- Novel therapeutic applications
Research on Alpha-1D Adrenergic Receptor has revealed important implications for neurodegenerative diseases.
- Biomarker development
- Therapeutic targeting
- Disease mechanism studies
α1D-AR expression in the nervous system:
- Brain regions: cortex, hippocampus, hypothalamus
- Spinal cord dorsal horn (pain transmission)
- Peripheral nervous system
α1D-AR activates multiple signaling pathways:
- Gq/11 protein coupling
- PLCβ activation
- IP3/DAG production
- Calcium mobilization
- Subtype-selective ligands development
- Understanding CNS vs peripheral effects
- Role in cognitive function
- Therapeutic potential for ADHD